Business
Ocumetics to Showcase First-In-human Results with Industry Leaders & Potential Strategic Partners at ASCRS Annual Meeting
(TheNewswire) Key Highlights   Early First-in-Human clinical results have dra...
About this update from Ocumetics Technology Corp
[{"type":"text","content":"Ocumetics to Showcase First-In-human Results with Industry Leaders & Potential Strategic Partners at ASCRS Annual Meeting\n(TheNewswire)\n\n\nKey Highlights\n\n \n\n\n\nEarly First-in-Human clinical\nresults have drawn the attention of industry leaders and\nseveral of the largest vision care technology companies in the\nworld. \n\n\n\nOcumetics will leverage the conference to further engage with global strategic partners to\naccelerate development and commercialization efforts. \n\n\n\n\nCalgary, Canada – TheNewswire - April 1, 2026 -\nOcumetics Technology\nCorp. (“Ocumetics” or the “Company”)\n(TSV:V OTC) (OTCQB: OTCFF) (FRA: 2QBO),\na leader in next generation ophthalmic\ntechnology, announced today that its leadership team will meet in\nWashington, D.C. with several potential ophthalmic strategic partners\nand leading industry stakeholders during the upcoming American Society\nof Cataract and Refractive Surgery (ASCRS) Annual Meeting. The team\nwill provide updates on the Company’s First-in-Human (FIH) clinical\nprogram and outline the next phase of its clinical development\nstrategy.\n\n\nDuring these meetings, Ocumetics will present the\nlatest results from its ongoing FIH clinical study evaluating the\nCompany’s accommodating intraocular lens technology (the\n“Ocumetics Lens”). The discussions will focus on early surgical\noutcomes, patient response, key learnings that are informing the\nCompany’s pathway toward expanding the study, and recent Ocumetics\nLens design advancements.\n\n\nThe Company will also provide an update on its planned\nGroup 2 surgeries, which represent the next stage of patient\nenrollment in its FIH clinical study. The Group 2 procedures are\nexpected to further evaluate the performance and consistency of the\nOcumetics Lens while providing additional clinical data to support the\nCompany’s broader regulatory and commercialization strategy.\n\n\n“Ocumetics is known for pushing the boundaries of\nophthalmic innovation,” said Dean Burns, President and CEO of\nOcumetics. “Group 1 surgeries provided valuable insights into both\nsurgical performance and patient outcomes of the Ocumetics Lens. Our\nmeetings at ASCRS will allow us to share these learnings directly with\npotential strategic partne...